Mark Toland: CEO of MMI (Medical Microinstruments)

Boston Scientific and Corindus

Toland was a senior vice president at Boston Scientific, where he built its global solutions business and led the US commercial team for its cardiovascular businesses, about $4 billion in revenue.¹

He joined Corindus Vascular Robotics in 2016 and led the launch of the CorPath GRX system. Siemens Healthineers bought Corindus for $1.1 billion in 2019. In 2020 he joined BioStar Capital, an early Corindus investor, as a partner and entrepreneur in residence.^1,2

Leading MMI

MMI hired Toland as CEO in January 2021, after Symani won its CE mark and completed its first human cases in Florence, Italy. The company moved its corporate home to the US in 2022 and won FDA De Novo authorization in 2024.^1,3

On October 8, 2026, MMI raised $125 million in a Series D led by BioStar Capital. It has about 50 systems installed and 3,500 procedures done, and Toland has said the focus now is turning adoption into scale.⁴

We've proven there is demand for robotic microsurgery at leading institutions around the world. Now, our focus is translating that adoption into scale.MMI Series D announcement

Sources

Photo: MMI, Our people.